(Eagle Health Holdings Limited was successfully listed on the Australian Stock Exchange on July 3, 2017)
Eagle Health Holdings The listing ceremony of the Australian Board of Directors (ASX) of Limited (stock code EHH) was held on July 3 at 12:00 in Sydney. This is the first Chinese eco-pharmaceutical industry to be listed on the Australian main board, and it is also the gorgeous appearance of a Chinese health care product brand in the international market. Thanks to the guidance and sponsorship of IDC, the Australian capital, Eagle Health Holdings went public. It was warmly welcomed by Australian and international investors and set a record for the largest listing and financing of "Chinese concept stocks" in the first half of 2017.
More than 100 guests and more than 10 Chinese and foreign media reporters attended and witnessed this historic moment, such as the main leaders of the Australian Stock Exchange, the commercial consul of the Chinese Embassy in Australia, the president of the Canberra Xinhua News Agency, and the former deputy minister of Australia. Ministry of Foreign Affairs, former Minister of Sports, Chairman of Australia Zhejiang Chamber of Commerce, Chairman of Australia Wenzhou Chamber of Commerce, IDC Capital Partners, etc.
Zhang Mingwang, Chairman of the Board of Directors of Holdings, spoke on behalf of the Board of Directors: "Eagle Health Holdings Limited is officially listed on the Australian Stock Exchange. This is an important milestone in Eagle's history. Listing is not the end, but a new starting point, towards internationalization and publishing. Success. The listing reflects Eagle's business model, growth potential, profitability, management team, and development prospects widely recognized by the capital market."
He said: "In recent years, with the improvement of China's consumption level, people's awareness of healthy life and active policies, China's health industry has ushered in a golden period. As a leading enterprise in the health care industry in Fujian Province, we have Responsibility and ability to connect Australian health products that meet the world's pharmaceutical standards with China's largest health product market. In addition, we are confident to share Dendrobium. Eagle and other precious Chinese herbal health products are made with Australian citizens."
He also said, “We have chosen to list on the Australian main board to build a bridge between China and Australia, to achieve complementary resources and markets, and to use Australia’s mature research, products and capital markets. At present, Eagle has cooperated with Monash University in Australia The cooperation has become the sole agent of natural treatment for onychomycosis in China. At the same time, it will also launch a diabetes patent. It also attracted 11 million Australian dollars (about 60 million yuan) from Nativa, South Africa’s largest healthcare company Long-term investment will open up sales markets. Africa. We will also use this bridge to bring Chinese medicine products to the international community and bring benefits to the world."
Eagle Health is a comprehensive eco-pharmaceutical company with a history of 16 years. In 2016, it integrated the R&D, production and sales of the top ten economic gold medals in Fujian Province and Xiamen. Walk at the forefront of traditional modernization. Traditional Chinese medicine is represented by Dendrobium "ancient" at home and abroad.
Eagle Health Group Co., Ltd. will rely on the R&D technology of the Australian health industry and the international capital market to seize the good momentum of China's main health industry, achieve rapid development, and reward shareholders with the best performance.